Biofermin (4517 JP) - Taisho (4581 JP): Merger Is a Done Deal
Taisho Pharma and subsidiary Biofermin (4517) have agreed to merge. The vote looks like a done deal. This is a short-dated rate of return trade.
233 Views
Taisho Pharma Seems the Best Suitor for Takeda’s Japan OTC Business
It was reported by several news media outlets that Blackstone, Bain Capital, CVC Capital Partners and Taisho Pharmaceutical are among the final...
448 Views
🇯🇵 JAPAN - Stress Tests Part 3 - Inventory, Fixed Asset & Free Cash Flows
FROM OPERATING TO FINANCING CASH FLOWS - Having examined Operating Cash Flow in our previous Insight, we shall look into the 'stressors' between...
318 Views
EM Breakout -- Add Exposure
The laundry list of current market conditions consistent with the profile of a bull market continues to grow, helping support our ongoing belief...
685 Views
Taisho To Launch Another DHG Pharma Tender
After the close on 28 February 2019, Taisho Pharmaceutical Holdings (4581 JP)announced it would launch another Tender Offer, this time to purchase...
614 Views